CLINICAL STUDY AGREEMENT

Protocol No. \_\_\_\_\_\_\_\_\_\_\_\_\_

This Clinical Study Agreement (“Agreement”) is entered into by and among:

The UNIVERSITY OF THE PHILIPPINES, the national university of the Philippines, created through Act No. 1870 and operating under Republic Act No. 9500, represented herein by the Chancellor of the University of the Philippines Manila, DR. CARMENCITA D. PADILLA, with office address at the 8th Floor, RCB Building, Philippine General Hospital, Manila, hereinafter referred to as the “**UNIVERSITY”** ;

and

The [NAME OF GOVERNMENT AGENCY/HOSPITAL], a \_\_\_\_\_ operating and existing under the laws of the Republic of the Philippines, with office address at \_\_\_\_, represented hereby its [Position of hospital or agency head], [NAME], hereinafter referred to as the “**Institution**”;

and

[NAME OF PRINCIPAL INVESTIGATOR], Filipino, single/married, and a resident of [house/unit number, building number/name, street, barangay, city], appointed as [position/title] under the Department of [name of department in the hospital] or College [name of college], hereinafter referred to as the “**Principal Investigator**”;

**WHEREAS,** the **UNIVERSITY** is created by law to serve as a research university in various fields of expertise and specialization by conducting basic and applied research and development, and promoting research in various colleges and universities, and contributing to the dissemination and application of knowledge;

**WHEREAS**, the parties have agreed to undertake a Clinical Study [Study] entitled, [state title of clinical study];

**WHEREAS**, the Institution has the appropriate facilities and has agreed that the Study be conducted in its premises;

**WHEREAS**, [state other relevant WHEREAS clauses];

**WHEREAS,** the performance of the Study is of mutual interest to the partiesThe parties therefore agree as follows:

1. **SCOPE OF WORK**
	1. **Conduct of the Study.** The parties agree to conduct the Study based upon the terms and conditions contained in this Agreement and in accordance with the **Protocol** attached as **Appendix A**.
	2. **Site Evaluation.** The UNIVERSITY will conduct an evaluation of the planned facilities to be used by the Institution for the Study before the performance of the Study and before implementation of the Study.
	3. **Principal Investigator/s.**
2. **Responsibilities of the UNIVERSITY**.
	1. To provide the Institution with the necessary background information needed for the appropriate and safe conduct of the Study;
	2. To ensure necessary training and orientation of the investigators and other personnel of the Institution involved in the Study in order to conduct the Study in accordance with the protocol;
	3. To register the Study into an open international publication register according to common practice before starting the patient recruitment;
	4. To inform the Institution of the completion of the Study;
	5. To provide training for medical personnel who will conduct the pulse oximetry screening;
	6. To designate a research assistant to conduct data collection on site;
	7. To provide the Institution with the data and documents needed for conducting the Study and guaranteeing the safety of the participants. The data and documents provided by the UNIVERSITY may be used solely for the conduct of this Study in accordance with this agreement.
3. **Responsibilities of the Institution**
	1. To act as the employer of the investigators and other personnel conducting the Study;
	2. To ensure that during the term of Study set forth in this agreement, the Investigators engaging in the Study do not initiate any other clinical Study at the Study site, which would delay recruitment of participants for this Study;
	3. To ensure that qualified and instructed personnel and adequate equipment are available for the Study and that the Study may also in other respects be conducted in safe conditions;
	4. To allow participation of the Investigators and when appropriate/needed also other personnel conducting the Study in Investigators meetings and other education arranged by the UNIVERSITY;
	5. To ensure that the Investigators are familiar with the details of the protocol and other liabilities and responsibilities defined in this agreement, and that Investigators are committed to act accordingly;
	6. To ensure that the participants are not simultaneously involved in any other clinical trials and that they are not participants to any investigations differing from the Study protocol;
	7. To allow monitoring and auditing at the Study site to be conducted by the UNIVERSITY, as well as domestic and foreign regulatory authorities, and, if necessary, to assist in the executing thereof.
	8. To provide the logbook of patients to the research assistant for participant selection;
	9. To provide pass or identification card for research assistant.
4. **Responsibilities of the Principal Investigator**
	1. To be fully acquainted with the protocol and all information and documents provided by the UNIVERSITY concerning the conduct of the clinical Study;
	2. To ensure that qualified and instructed personnel, as well as adequate equipment are available for the Study, and that the Study can also in all other respects be conducted under safe conditions;
	3. To conduct the Study in accordance with the protocol as approved by the UP Manila Ethics Committee including potential approved amendments thereto;
	4. To immediately notify the UNIVERSITY of all necessary amendments to the protocol or any deviations from the protocol, which are imperative to avoid immediate danger to the participants, and immediately execute necessary precautions for the protection of the participants;
	5. To ensure that all participants have given the proper written informed consent to their participation in the Study and have received sufficient information of the Study and benefits, risks, and disadvantages related thereto for giving the consent;
	6. To ensure that all the persons assisting in the Study and, if necessary, also others engaging in the treatment of the participants have been properly informed of the protocol, investigational products and their obligations and duties relating to the Study;
	7. To immediately report to the UNIVERSITY all serious adverse events apart from the events, which according to the protocol or any other document, such as Investigator’s Brochure, do not require immediate reporting, and also to follow the protocol with respect to the reporting of adverse events and abnormal laboratory values;
	8. To ensure accuracy, completeness, reliability, and timeliness of the information submitted to the UNIVERSITY on the case report forms and all required reports, including those in electronic format, and deliver the case report forms and other required reports to the UNIVERSITY;
	9. To take care of the registration and notification of information necessary for the invoicing to the financial administration of the Study site at agreed intervals, and
	10. To act in co-operation with the UNIVERSITY relating to monitoring visits and audits.
5. **CASE REPORT FORMS**.
	1. UNIVERSITY will provide the Institution with a sufficient quantity of Case Report Forms ("CRF's"), necessary questionnaires or other required documentation to conduct the Study.
	2. All original CRF's will be the sole property of the UNIVERSITY.
	3. All other original records of the work completed under this Agreement, including patient medical records, laboratory records and reports, scans, films and information on pre-existing Institution databases will be Institution property. Institution will retain a copy of all Study documents for internal research, teaching and archival purposes.
6. **FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS** - The Institution must, if necessary, ensure that all investigators listed in the Study protocol and conducting the Study provide the UNIVERSITY with all information on their significant financial commitments, such as patent and all other intellectual property rights related to the Study, ownership of shares in the Study Devices.
7. **STUDY DEVICES** [only if research involves a study device]
	1. The Study Device which consists [description of the device] to be used in the Study shall be the sole property of the UNIVERSITY.
	2. The UNIVERSITY shall supply sufficient amount of appropriately labelled Study Devices and other materials, substances and equipment (including necessary materials for packing and shipment) without cost for the use in the Study site and keep records of the supply, reception, use, return, and destruction of the Study Devices.
	3. The Institution and the principal investigators are obliged to comply with the instructions of the Institution regarding receipt and handling of the Study Devices and to use the Study Device solely as defined in the protocol in order to conduct the Study defined in this agreement.
	4. The Institution and the principal investigators shall be responsible for the Study Device being stored, handled, and recorded in accordance with the protocol.
	5. Upon the termination of this agreement, the Institution and the principal investigator shall be responsible for the return of the Study Devices unless otherwise instructed in writing by the UNIVERSITY.
8. **COMPENSATION, INVOICING AND PAYMENT** [only as may be applicable]
	1. In accordance with the budget set forth in **Appendix B** and according to the schedule defined in **Appendix C**, the costs accrued by the Study shall be compensated against a specified invoice.
	2. The budget includes all expenses, compensations, taxes and other similar payments, such as “social security payment” paid by the Institution, administrative over-heads and a possible VAT.
	3. The UNIVERSITY shall compensate only for the completed patient visits, laboratory and other investigations, pharmacy costs, and other comparable costs as defined by the protocol and approved by the UNIVERSITY. Any other expenses shall not be compensated for without a separate written agreement concluded with the UNIVERSITY thereof. If an amendment to the protocol would cause additional costs, their reimbursement shall be agreed separately between the UNIVERSITY and the Institution.
	4. The UNIVERSITY shall compensate for any extra traveling costs attributable to the Study participant using public transportation and caused by his/her participation in the Study. A taxi may be used only if it is regarded necessary by the investigator due to the state of health of the participant or the nature of the Study.
	5. The UNIVERSITY shall bear the costs of all necessary training, meetings, other travelling and events related to the Study.
	6. Invoicing address and the contact person of the UNIVERSITY:

 [NAME OF CONTACT PERSON]

 [Name of Office, Department, Unit]

 [Complete address and contact number]

* 1. The Institution shall be responsible for invoicing the costs incurred by the Study from the UNIVERSITY. The costs accrued in each calendar month/year must be invoiced by [day]/[month]/[year]. All costs related to the Study must be invoiced from the UNIVERSITY by [day]/[month]/[year] at latest.

At least the following information must be included in each invoice:

* Name and site of the Study,
* Number of patients, and approved visits (other procedures if applicable) and the date thereof (including the participant numbers),
* Unit price of the conducted investigation, taxes not included,
* Potential refunds and discounts, provided that they have not been taken into account in the unit price.
	1. The investigator shall report on the progress of the Study to the financial administration of the Institution at agreed intervals for invoicing. The invoicing must be based on visits (or procedures) approved by the UNIVERSITY.
	2. All payments relating to the Study, including compensations paid to the investigators and other research personnel shall be directed to the account indicated in the invoice of the Institution.
1. **RIGHTS OF THE UNIVERSITY**
	1. The representatives of the UNIVERSITY shall have the right to gain access to the Study site and the patient records and other documents related to the Study in order to ensure correctness of the Study records and the proper conduct of the Study.
	2. The informed consent of the participants is required for the use of documents containing their personal data.
	3. The investigators shall co-operate with the UNIVERSITY relating to the aforementioned monitoring visits and audits. No separate compensation shall be paid to the investigators for the potential additional work due to monitoring and audits.
2. **CONFIDENTIALITY**
	1. Each party shall keep in confidence all information exchanged between them in the course of the Study. The Institution shall keep in confidence especially all information related to and accrued in connection with the Study, the Results, documents, and electronic records (hereinafter “Confidential Information”). All documents and electronic records that contain Confidential Information must be stored in a manner that no third party may have access thereto.
	2. *Exceptions. -* The confidentiality obligation shall not, however, be applied to Confidential Information, which:
3. Was, as evidenced, in the possession of the receiving party prior to receipt of the confidential information from the other party,
4. Has been publicly available or has become publicly available through no act or omission by the party or its employee or a consultant or breach of this agreement,
5. The party has received from a third party without any obligation of confidentiality and which has a right to deliver such information to the other party, or On ground of law has to be delivered.

Any party invoking and exception set forth above has the burden of proof with respect to the existence of such an exception.

* 1. Each party shall promptly return to the other party and Confidential Information no longer needed for the purposes of this agreement or if so requested by the other party.
	2. Should any third party, e.g. Regulatory Authority demand access to Confidential Information on grounds of law, the party shall without any delay and prior to making such a disclosure notify the other party of such a demand in writing. The party may then deliver only the specified Confidential Information, which the request concerns.
1. **STUDY REGISTER AND PERSONAL DATA PROTECTION**
	1. A Study register will be created in connection with the Study, the controller of which will be the principal investigators and the Institution where the Study is being conducted for purposes of application of the Data Privacy Act.
	2. The Study register shall be confidential and may be accessed only by the persons involved in the Study as well as the UNIVERSITY for verification purposes. Data exchange shall be de-identified and kept private in accordance with the Data Privacy Act.
	3. The UNIVERSITY including its representatives, is obliged to keep confidential the personal data of the subjects accrued in connection with the Study.
2. **DATA AND RESULTS ACCRUED IN CONNECTION WITH THE STUDY**

All information, documents, reports, materials and other results accrued in connection with this Study apart from the patient records and other data collected by the Institution for its own use (hereinafter “Results”) are the property of the UNIVERSITY, the use of which the UNIVERSITY may decide independently.

1. **INTELLECTUAL PROPERTY RIGHTS**
	1. All copyrights, industrial rights and other intellectual property rights generated as a result of this Study or in connection thereto and which are related to the Results are the property of the UNIVERSITY.
	2. The UNIVERSITY has the exclusive right of exploitation of the aforementioned copyrights, industrial rights and other intellectual property rights.
	3. The Institution is obliged to ensure, that all inventions created in the Study or as a result of the research work related thereto, and copyrights, industrial rights and other intellectual property rights which are related to the Results shall be transferred to the UNIVERSITY regardless of whether such rights shall transfer to the Institution by virtue of law.
	4. The investigator can take part in the protection of industrial and other intellectual property rights on the request by the UNIVERSITY and on its expenses.
	5. **Intellectual Property Agreements.** Institution will obtain patent and copyright agreements to effectuate the purposes of this Agreement from all individuals who perform any part of the Study.
2. **PUBLICATION OF RESULTS**
	1. [If applicable] The Study being a multi-center Study, no results concerning the Study may be published prior to the receipt and analysis of the Study results from all Study centers or the Study has been completed in all centers.
	2. [If applicable] The principal investigator of the entire multi-center Study based in Institution-the UNIVERSITY or the entity responsible for the publication of the Study results shall be responsible for publication of the Study results.
	3. [If applicable] Other investigators may not publish any separate publications concerning the Study prior to the publication of Study results covering all Study centers. In the event the principal investigator of the entire multi-center Study or the entity in charge of the publication decides, that the Study results of a multi-center Study shall not be published, an individual investigator may publish his/her own Study records. the UNIVERSITY shall inform the investigators of the decision not to publish the results of a multi-center Study.
	4. Any possibly patentable Results or Results, which could be protected by any other industrial rights, shall not be published prior to filing the patent applications or other industrial property protection related thereto with the appropriate authorities.
	5. Upon termination of the Study, the investigator has apart from the aforementioned restrictions concerning multi-center trials, the right to independently analyse his/her own Study results and publish them with the exception to information regarded as confidential by the UNIVERSITY. the UNIVERSITY shall obtain the manuscript of the publication for its assessment sixty (60) days prior to it being submitted for publication. Should the UNIVERSITY inform the investigator of its intention to apply for a patent relating to the facts presented in the publication, the publication shall be further postponed for a maximum period of 120 days
3. **ASSIGNMENT**. The parties may not assign this agreement, any part thereof, or any right or obligation related thereto to any third party without the prior written consent of the other party.
4. **INDEMNIFICATION**.
	1. The UNIVERSITY shall indemnify and hold harmless the Institution from any and all liability of Study subjects, loss, or damage it may suffer as a result of the UNIVERSITY’S negligence or breach of contract or caused by the Study Devices and medicines, compliance with the protocol, or use of the Results.
	2. The Institution agrees to indemnify and hold harmless the UNIVERSITY from any and all liability of Study participants, loss, or damage it may suffer as a result of the Institution’s negligence or breach of contract.
5. **ENSURING CONDUCT OF THE STUDY**. The Institution shall be responsible for ensuring sufficient and appropriate resources for the conduct of the Study, and that no other than legal obligations or commitments of the Institution of the Study cause unreasonable damage to or delay in conducting the Study as set forth in this agreement.
6. **FORCE MAJEURE**
	1. Any event occurring after signing the agreement, which a party could not reasonably have taken into account at the time of the conclusion of the agreement and which prevents or delays the affected party from fulfilling of its obligations under the agreement or makes the fulfilment thereof unreasonably difficult and which can not be overcome without unreasonable loss of time or cost, shall constitute an event of force majeure.
	2. An event of force majeure shall include: strike, war, revolt, import or export prohibition, acts of God, interruption of public traffic or distribution of energy, legal labour dispute, fire or any other reason having as severe and unusual effects beyond the control of the party.
	3. If a party would wish to invoke existence of an event of force majeure as a cause for the non-compliance with any of its obligations under the agreement or delay or exemption from liability, it shall without delay inform the other party of the delay or termination of its contractual obligation in writing.
7. **RETENTION AND DESTRUCTION OF STUDY RECORDS**
	1. The Institution shall store the original Study results and codes at minimum fifteen (15) years after termination of the Study. The storage of Study records is included in the compensation paid by the UNIVERSITY to the Institution for the conduct of the Study.
	2. The UNIVERSITY shall notify the Institution in good time in advance and in writing if it wants the Institution to keep the records or codes after the above-mentioned 15 years.
	3. The UNIVERSITY shall notify the Institution of the time after which the records related to the Study must no longer be stored, and reimburse the Institution all additional costs incurred due to the storage exceeding fifteen (15) years. With respect to storage of records, the instructions set forth in Sections 4.9. and 5.5 of the ICH GCP are followed.
8. **TRANSPARENCY**. Investigators shall declare that the UNIVERSITY has provided her/him with funding for the Study whenever she/he writes or speaks in public about a matter that is the subject of this agreement or about any other issue relating to the UNIVERSITY.
9. **COMPLAINTS AND LIABILITIES**
	1. A party is obliged to notify the other party immediately in writing of all errors, omissions, and deficiencies detected in the conduct of the other party based on this agreement. Thereafter, the defaulting party has a duty to correct the reported error, omission, or deficiency.
	2. A party shall be liable to compensate the other party the damages caused by its breach of contract. The parties shall not, however, be liable for any indirect or consequential damages. Except for the damages caused deliberately or by gross negligence.
10. **TERM AND TERMINATION OF THE AGREEMENT**
	1. This agreement shall become effective upon signing by both parties. The agreement shall continue in effect until \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ or until both parties have fulfilled their obligations set forth by this agreement.
	2. Without prejudice to the term of the agreement, a party may terminate this agreement with immediate effect, if:
		1. The other party is in material default of any of its obligations under this agreement and the breach is of significant importance to the other party,
		2. The other party fails to comply with its obligations under this agreement and has not corrected its default, omission, or deficiency within four (4) weeks after the non-defaulting party has given the defaulting party written notice thereof.
	3. The principal investigator, the Institution, or the UNIVERSITY has the right to suspend the conduct of the Study and serve notice of termination with immediate effect due to any cause relating to the safety of the participants or any ethical reason.
	4. In the event a complaint based on the Study has not led to correction of an error or deficiency, the UNIVERSITY shall in addition have the right without separate obligation of compensation or refund to suspend the Study and terminate immediately in writing this agreement in the following circumstances:
		1. If a favorable opinion of the Ethics Committee is not obtained,
		2. If no subjects have been recruited within \_\_\_\_\_months followed by the initial visit of the UNIVERSITY,
		3. If the Institution has enrolled Study participants, who do not fulfill the criteria set for the subjects as defined by the protocol,
		4. If the Institution does not follow the protocol,
		5. If the Institution fails to comply with the 2017 National Ethical Guidelines for Health and Health-related Research.
		6. If the principal investigator gives notice or is given notice by the unit conducting the Study or otherwise ceases to work for the Study as defined by this agreement, and the parties fail to reach mutual understanding on the new principal investigator, or
		7. If the UNIVERSITY decides to terminate the Study for scientific, ethical, or administrative reasons.

*Provided that*, when the UNIVERSITY serves notice of termination due to any cause referred to in the preceding paragraph, the UNIVERSITY shall be oblige to compensate the Institution all necessary, irrevocable, documented, and direct costs incurred by the suspension of the Study due to the conduct of the Study.

The terms and conditions and responsibilities relating to the rights of the UNIVERSITY and the authorities, confidentiality of information, the Study register and personal data protection, data and records accrued as a result of the Study, intellectual property rights, publication of results, archiving and destroying of the Study records and governing law and dispute resolution shall survive termination or cancellation of this agreement.

1. **GOVERNING LAW**. This agreement shall be governed by the laws of the Republic of the Philippines as well as international guidelines relating to good clinical practices.
2. **DISPUTE RESOLUTION AND FORUM**
	1. In case of disputes, claims and controversies arising from the interpretation and application of this Agreement the parties agree to freely and voluntarily submit themselves to consultation and negotiation to amicably settle the dispute;
	2. Should the parties fail to reach an amicable settlement, the dispute shall be administratively settled or adjudicated in the manner provided in Chapter 14 of Executive Order No. 292 (Administrative Code of 1987) in relation to the RULES ON ALTERNATIVE DISPUTE RESOLUTION (ADR), or any amendments or revisions thereto, in accordance with the “DISPUTES BETWEEN NATIONAL GOVERNMENT AGENCIES” issued by the Office of the Solicitor General on March 22, 2010.
3. **PUBLICITY**
	1. Neither party will identify the other in any promotional advertising or other promotional materials to be disseminated to the public or use the name of any faculty member, employee, or student or any trademark, service mark, trade name, or symbol of the other.
	2. Notwithstanding anything to the contrary, the UNIVERSITY agrees to allow publicly registered information about the Study to appear on Institution’s Clinical Trials Directory website.
4. **NOTICES**
	1. *Form of Notice*. All notices, requests, claims, demands, and other communications between the parties shall be in writing.
	2. *Method of Notice*. All notices shall be given (i) by delivery in person (ii) by a nationally recognized next day courier services, (iii) by first class, registered or certified mail, postage prepaid; or (iv) by email.
	3. *Receipt of Notice*. All notices shall be effective:
		1. upon receipt by the party to which notice is given,
		2. on the day the mail is returned to sender because the addressee no longer resides at the given address in this contract without notifying the other party of the new address, or
		3. after two (2) failed attempts to personally deliver the notices, requests, claims, demands and other communications, the party delivering the notice may leave the notice, request, claim, demand or other communications to a person of legal age residing or working in the address specified in No. 5 of Article XVII or to the supervisor of the construction work in the site;
		4. on the date of receipt of the email.
	4. *Refusal of Delivery*. Rejection or other refusal to accept or the inability to deliver because of change of address where the other party was not notified thereof shall be deemed to be receipt of the notice as of the date of such rejection, refusal or inability to deliver.
	5. *Party to notify*. All notices, requests, claims, demands and other communications shall only be valid, effective and binding if received by the following offices in the addresses indicated below:

 For the UNIVERSITY:

 Office of the Chancellor

 8th Floor, Right Central Block Building

 Philippine General Hospital

 Taft Avenue, Ermita, Manila 1000

 Email: oc@upm.edu.ph

 For Institution:

 Office of the Director

Name of hospital: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 Address: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 Email: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **MISCELLANEOUS**
	1. **Amendment.** The parties may mutually amend the terms and conditions of this Agreement in writing.
	2. **Divisibility**. If any provision of this Agreement becomes or is declared illegal, invalid, or unenforceable, such provision will be divisible from this Agreement and will be deemed to be deleted from this Agreement. If such deletion substantially alters the basis of this Agreement, the parties will negotiate in good faith to amend the provisions of this Agreement to give effect to the original intent of the parties.
	3. **Independent Contractors**. Institution and UNIVERSITY are independent contractors and neither is an agent, joint venturer, or partner of the other.
	4. **Entire Agreement**. This agreement, including its Appendices, represents the entire understanding between the parties with respect to the conduct of the Study as described in Section 2 and supersedes all prior oral or written agreements between the parties related thereto.
	5. **Non-waiver**. - The failure of any party to enforce any term or provision hereof shall not be construed to be a waiver of such term or provision and shall in no way affect the right of such party thereafter to enforce such term or provision or any other term or provision thereof.
	6. **Counterparts**. This Agreement may be executed in multiple counterparts, each of which will be deemed an original, but all of which will constitute one and the same Agreement, and the signature pages from any counterpart may be appended to any other counterpart to assemble fully executed counterparts. Counterparts of this Agreement also may be exchanged via electronic PDF copy, and an electronic PDF copy of any party’s signature will be deemed to be an original signature for all purposes.

 IN WITNESS WHEREOF, these duly authorized representatives of the parties hereby execute this Agreement, including all the terms and conditions which follow this \_\_\_\_\_\_\_\_\_\_\_\_\_\_ in the City of Manila, Philippines.

UNIVERSITY OF THE PHILIPPINES [NAME OF AGENCY/HOSPITAL]

by: by:

CARMENCITA D. PADILLA, MD, MAHPS [NAME OF DIRECTOR/representative]

Chancellor, UP Manila Director

PRINCIPAL INVESTIGATOR/S:

DR. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, MD

Department of \_\_\_\_\_, [Name of Hospital]

DR. \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, MD

Department of \_\_\_\_\_, [Name of Hospital]

SIGNED IN THE PRESENCE OF:

EVA MARIA CUTIONGCO-DE LA PAZ, MD [Name of witness of Institution]

Vice Chancellor for Research and [Position]

Executive Director, National Institutes of Health

**ACKNOWLEDGMENT**

REPUBLIC OF THE PHILIPPINES)

City of Manila ) S.S.

 **BEFORE ME**, a Notary Public for and in City of Manila this \_\_\_th day of \_\_\_\_\_\_\_\_\_\_\_\_ 2018, personally appeared:

 Name ID No. Issuing Office

CARMENCITA D. PADILLA \_\_\_\_\_\_\_\_\_\_\_\_\_ \_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

[Name/Institution representative] \_\_\_\_\_\_\_\_\_\_\_\_\_ \_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

[NamePrincipal investigator]\_\_\_\_\_\_\_\_\_\_\_\_\_ \_ \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Known to me and has been identified by me based on competent proof of identity to be the same persons who executed the foregoing instrument, and they acknowledged to me that the same is their free and voluntary act and deed as well the entities they represent. This instrument consists of eleven (11) pages including this page on which this acknowledgement is written, signed by the parties hereto together with their two instrumental witnesses on each and every page hereof.

 **IN WITNESS WHEREOF**, I have hereunto affixed my signature and notarial seal this \_\_\_\_day of \_\_\_\_\_\_\_\_\_\_\_ 2018.

Doc. No. \_\_\_\_\_;

Page No. \_\_\_\_\_;

Book No. \_\_\_\_\_;

Series of 2018